Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

This is an interventional treatment trial for Angiogenesis Inhibitors，Ovarian Neoplasms Read More

Inclusion Criteria:

1. 18 years to 70 years;
2. Had a histologically or cytologically confirmed diagnosis of epithelial ovarian cancer；
3. unfit for radical surgery and had received second-line chemotherapy，the disease still progressed or can not tolerate the chemotherapy;
4. Had a disease status that was measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST, version1.1);
5. Had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2;
6. Had a life expectancy of at least 12 weeks;
7. Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥90g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.5×the upper limit of normal (ULN), and b) ALT and AST≤2.5×the ULN (If liver metastases, serum creatine ≤ 1.5 x ULN);
8. Had not gastrointestinal diseases that lead to malabsorption or impact Drug absorption;
9. had good compliance;
10. Signed and dated informed consent.

Exclusion Criteria:

1. patients who had received anti-vascular therapy;
2. Allergic to any ingredients of Apatinib;
3. Participated in other drug clinical researchers within four weeks;
4. Have a variety of factors that affect oral medication (such as can not swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.)
5. Severe infection;
6. Patients with serious cardiovascular diseases,such as unstable angina, grade 3-4 heart dysfunction (NYHA Standard), congestive heart failure, poor-controlled arterial hypertension despite standard medical management;
7. Patients who received major surgical operations within 4 weeks before screening;
8. Patients who manifested arterial/venous thrombus events, e.g.cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, etc., within 12 months before screening;
9. Past or concurrent with other malignancies, except for cured skin basal cell carcinoma and cervical in situ cancer;
10. Have a history of psychiatric abuse and can not quit or have mental disorders.